Pfizer Ltd

Pfizer Ltd

₹ 3,801 -0.12%
30 May - close price
About

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1]
It is the 3rd largest multinational pharmaceutical company in India.[2]

Key Points

Product Portfolio
Presently, the company sells ~150 different products across 15+ therapeutic areas viz. anti-allergic, anti-diabetic, anti-infectives, cardiovascular, gastrointestinal, neurology, pain, respiratory, vitamin/minerals, antibiotics, etc.[1][2]

  • Market Cap 17,387 Cr.
  • Current Price 3,801
  • High / Low 4,662 / 3,407
  • Stock P/E 28.9
  • Book Value 701
  • Dividend Yield 0.92 %
  • ROCE 26.2 %
  • ROE 19.8 %
  • Face Value 10.0

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 29.2%

Cons

  • The company has delivered a poor sales growth of 4.26% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
502 515 595 593 535 749 636 676 550 593 637 622 573
393 329 392 397 409 463 447 481 384 401 406 418 391
Operating Profit 109 186 203 197 126 286 189 195 165 192 232 203 182
OPM % 22% 36% 34% 33% 24% 38% 30% 29% 30% 32% 36% 33% 32%
45 17 12 15 37 12 15 18 17 -118 213 27 12
Interest 4 3 5 4 4 2 2 2 4 4 3 4 3
Depreciation 28 27 28 27 27 27 27 27 34 27 26 26 26
Profit before tax 122 173 183 180 132 269 175 184 145 43 415 201 165
Tax % 16% 28% 28% 22% 24% 26% 18% 22% 13% 25% 25% 25% 21%
Net Profit 103 124 131 141 101 200 143 144 126 33 311 151 130
EPS in Rs 22.52 27.20 28.72 30.87 21.98 43.70 31.25 31.46 27.50 7.12 68.00 32.93 28.34
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
1,093 1,049 1,112 1,853 2,012 1,966 1,969 2,082 2,152 2,239 2,611 2,425
897 865 872 1,438 1,579 1,616 1,468 1,516 1,578 1,526 1,775 1,616
Operating Profit 197 184 239 414 433 350 501 566 574 712 836 809
OPM % 18% 18% 22% 22% 22% 18% 25% 27% 27% 32% 32% 33%
92 519 109 44 97 232 114 167 183 81 63 134
Interest 2 2 1 2 1 2 1 2 11 15 11 13
Depreciation 10 8 8 250 58 63 66 71 103 109 115 106
Profit before tax 278 694 340 207 470 517 548 660 642 669 773 824
Tax % 33% 27% 35% 66% 35% 35% 34% 35% 21% 26% 21% 24%
Net Profit 185 503 221 70 305 337 360 429 509 498 613 624
EPS in Rs 61.86 168.62 74.01 15.26 66.67 73.62 78.71 93.79 111.29 108.77 133.90 136.38
Dividend Payout % 20% 19% 486% 82% 22% 27% 25% 24% 297% 32% 26% 29%
Compounded Sales Growth
10 Years: 9%
5 Years: 4%
3 Years: 4%
TTM: -7%
Compounded Profit Growth
10 Years: 11%
5 Years: 11%
3 Years: 6%
TTM: -2%
Stock Price CAGR
10 Years: 14%
5 Years: 9%
3 Years: -2%
1 Year: -11%
Return on Equity
10 Years: 16%
5 Years: 18%
3 Years: 20%
Last Year: 20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
30 30 30 46 46 46 46 46 46 46 46 46
Reserves 1,275 1,665 629 1,927 2,118 2,373 2,637 2,966 3,350 2,347 2,819 3,162
-0 -0 -0 2 2 2 2 2 2 63 39 41
277 365 318 638 722 840 1,004 926 1,007 810 997 752
Total Liabilities 1,582 2,060 977 2,614 2,888 3,261 3,690 3,940 4,405 3,266 3,901 4,001
31 26 20 944 925 902 950 886 973 894 869 749
CWIP 0 0 3 13 3 15 1 -0 1 3 1 8
Investments 48 46 44 43 37 -0 -0 -0 -0 -0 -0 -0
1,502 1,988 909 1,614 1,923 2,343 2,739 3,054 3,432 2,369 3,030 3,244
Total Assets 1,582 2,060 977 2,614 2,888 3,261 3,690 3,940 4,405 3,266 3,901 4,001

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
24 -16 132 113 345 329 332 98 323 427 667 356
278 626 103 68 -701 -250 -238 35 1,530 -469 -575 -36
-14 -43 -1,360 -1 -62 -83 -110 -110 -164 -1,571 -181 -346
Net Cash Flow 288 567 -1,125 181 -417 -3 -17 23 1,690 -1,613 -88 -26

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 47 49 57 32 26 20 29 30 29 18 17 23
Inventory Days 186 181 148 191 167 148 147 189 198 199 173 175
Days Payable 138 165 156 165 157 178 245 213 197 130 102 91
Cash Conversion Cycle 95 65 49 58 36 -10 -69 6 31 87 89 107
Working Capital Days 71 7 25 7 -9 -46 -57 -15 -7 13 -7 7
ROCE % 23% 19% 29% 24% 22% 17% 21% 23% 20% 23% 29% 26%

Shareholding Pattern

Numbers in percentages

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92
2.51 1.93 1.87 1.89 2.07 2.07 2.13 2.20 2.55 2.55 2.77 2.80
14.41 14.96 14.31 14.63 15.15 15.15 15.03 15.06 14.83 14.88 14.93 14.89
19.16 19.18 19.89 19.55 18.86 18.86 18.92 18.82 18.70 18.65 18.39 18.38

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents